EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Emerging Gene Therapies for Alzheimer’s and Parkinson’s Diseases: An Overview of Clinical Trials and Promising Candidates

Will S Roberts, Shawn Price, Michael Wu, Mayur S Parmar

Cureus · 16.08.2024

DOI: 10.7759/cureus.67037 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cureus, erschienen am 16.08.2024. Verfasst von Will S Roberts und 3 weiteren Autor:innen. Beteiligte Einrichtung: Osteopathic Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine Nova Southeastern University, Clearwater, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy as a disease-modifying therapeutic approach for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), is a promising avenue. Promising results in the preclinical studies involving rodents and nonhuman primates utilizing gene therapy have led to multiple clinical trials evaluating various genes of interest for AD and PD. In AD, clinical trials are assessing gene therapy involving brain-derived neurotrophic factor (BDNF) and other targets such as apolipoprotein E2 (APOE2) and human telomerase reverse transcriptase (hTERT). In PD, clinical trials are evaluating gene therapy delivering neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF). Additionally, gene therapy delivering enzymes aromatic L-amino acid decarboxylase (AADC) and glutamic acid decarboxylase (GAD) are also being evaluated for PD. All these trials primarily utilized adeno-associated virus (AAV) to deliver the above transgene of interest. This review summarizes the current clinical trials involving gene therapy for AD and PD. It also discusses the challenges and opportunities associated with the gene therapy approach in AD and PD and ongoing developments related to increasing the safety and efficacy of the gene therapy for long-term outcomes, which include evaluation of various serotypes and administration routes. This comprehensive review emphasizes translating preclinical findings into clinical trials, further directions, and the potential for this promising therapeutic approach to alleviate neurodegenerative disease.

Schlagwörter

Stichwörter der Autor:innen

adeno-associated virus (aav)alzheimer's diseasechallenges and opportunitiesclinical trialsgene therapeuticsgene therapyneurodegenerative diseasesparkinson' s disease

Autor:innen und Institutionen

  • Osteopathic Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine Nova Southeastern University, Clearwater, USA.
  • Foundational Sciences, Dr. Kiran C. Patel College of Osteopathic Medicine Nova Southeastern University, Clearwater, USA.

Zitieren

APA

Roberts, W. S., Price, S., Wu, M., & Parmar, M. S. (2024). Emerging Gene Therapies for Alzheimer’s and Parkinson’s Diseases: An Overview of Clinical Trials and Promising Candidates. Cureus. https://doi.org/10.7759/cureus.67037

Vancouver

Roberts WS, Price S, Wu M, Parmar MS. Emerging Gene Therapies for Alzheimer’s and Parkinson’s Diseases: An Overview of Clinical Trials and Promising Candidates. Cureus. 2024. doi:10.7759/cureus.67037

BibTeX
@article{Roberts2024,
  author = {Roberts, Will S and Price, Shawn and Wu, Michael and Parmar, Mayur S},
  title = {Emerging Gene Therapies for Alzheimer’s and Parkinson’s Diseases: An Overview of Clinical Trials and Promising Candidates},
  journal = {Cureus},
  year = {2024},
  doi = {10.7759/cureus.67037}
}
Kostenlos starten →